Highest-materiality recent filing
Acumen nominates two EBD Alzheimer's candidates (ACU301, ACU401); IND in mid-2027
Nominated ACU301 (bispecific from sabirnetug) and ACU401 (novel AβO-selective antibody ACU234).
Acumen reports FY2025 net loss $121.3M; cash $116.9M; ALTITUDE-AD topline due late 2026
Net loss $121.3M for FY2025 ($102.3M in FY2024); R&D expenses rose to $104.9M.
Acumen raises $35.75M, reports positive EBD preclinical data with 14-40x brain penetration
Gross proceeds of $35.75M from private placement of 10,833,331 shares at $3.30/share; led by RA Capital.
Acumen reports Q3 net loss $26.5M; cash $136.1M supports ops into early 2027
Cash, equivalents & marketable securities $136.1M at Sept 30, down from $166.2M at June 30; runway into early 2027.
Acumen appoints George Golumbeski as Chairman, replaces Sean Stalfort
Dr. George Golumbeski appointed as director and Chairman of Board, effective Nov 6, 2025.
Acumen reports Q2 2025 net loss $41M, cash $166.2M; Phase 2 Alzheimer's topline expected late 2026
Cash, equivalents, and marketable securities totaled $166.2M as of June 30, 2025, expected to fund operations into early 2027.
Acumen Pharma enters Alzheimer's collaboration with JCR; up to $555M in milestones
JCR receives upfront payment (undisclosed) plus $9.25M option fee if Acumen exercises right to develop two candidates.
Acumen Pharma Q1 net loss $28.8M; Phase 2 Alzheimer's trial fully enrolled, results late 2026
Net loss $28.8M in Q1 2025 ($14.9M Q1 2024); loss from operations $30.4M vs $17.8M.
Acumen 2024 net loss $102.3M; cash $231.5M; ALTITUDE-AD enrollment complete
Net loss $102.3M vs $52.4M in 2023; R&D spend $93.8M (up 122%) driven by ALTITUDE-AD trial.
Acumen Pharma FY2023 net loss $52.4M; cash $306.1M; Phase 2 AD trial to start H1 2024
Net loss $52.4M in FY2023 vs $42.9M in 2022; operating loss $61.1M.
Acumen reports $306M cash, runway into H1 2027; plans Phase 2-only ALTITUDE-AD study
Cash, cash equivalents and marketable securities ~$306M as of Dec 31, 2023 (preliminary, unaudited).
Acumen appoints Dr. James Doherty as President and Chief Development Officer
Dr. James Doherty appointed President and Chief Development Officer effective Feb 1, 2024, reporting to CEO Daniel O'Connell.
Company posted updated corporate presentation on its website with additional biomarker data for ACU193.
Acumen reports Q3 net loss $13M, plans Phase 2 AD trial H1 2024, secures $50M credit facility
Phase 2 ALTITUDE-AD trial expected to initiate H1 2024 after positive FDA feedback on study design.
Acumen updates ACU193 Phase 1 subcutaneous trial to mid-2024; secures $50M credit facility
Projected mid-2024 initiation of Phase 1 subcutaneous trial for ACU193.
Acumen licenses Halozyme ENHANZE tech for subcutaneous ACU193; seven-figure upfront
Upfront payment in the seven-figure range for non-exclusive license to Halozyme's ENHANZE drug delivery technology.
Phase 1 INTERCEPT-AD trial met primary/secondary objectives; ACU193 showed 25% amyloid plaque reduction at 60 mg/kg (p=0.01).
Acumen Pharmaceuticals prices public offering of 16.8M shares at $7.75/share
Offering of 16,774,193 shares at $7.75 each; underwriters have 30-day option for up to 2,516,128 additional shares.
Acumen's ACU193 Phase 1 meets endpoints; plaque reduction up to 25%, low ARIA-E rate
60 mg/kg Q4W cohort showed 25% mean amyloid plaque reduction at day 63; 25 mg/kg Q2W showed 20% at day 70.
Company plans to offer shares of common stock; no terms disclosed.
Acumen reports FY2022 net loss $42.9M; Phase 1 ACU193 enrollment completed, topline Q3 2023
Cash, cash equivalents and marketable securities of $193.4M as of Dec 31, 2022, expected to fund operations through 2025.
Acumen updates INTERCEPT-AD trial enrollment, dose reduction for Cohort 7
Expects enrollment completion Q1 2023, topline data Q3 2023.
Acumen Q3 net loss $10.7M; INTERCEPT-AD Phase 1 on track, FDA Fast Track granted
Cash, equivalents & marketable securities $200.2M at Sep 30, 2022, sufficient through 2025.
Acumen's ACU193 receives FDA Fast Track designation for early Alzheimer's disease
ACU193 is first clinical-stage monoclonal antibody selectively targeting toxic soluble amyloid beta oligomers (AßOs).
Acumen Q2 net loss $10.2M; cash $209.9M; Phase 1 topline H1 2023; director resigns
Cash, cash equivalents and marketable securities $209.9M as of June 30, 2022; expected runway through 2025.
Acumen Q1 2022 net loss $9.1M; cash $216.7M, runway through 2025
Cash, cash equivalents and marketable securities totaled $216.7M as of March 31, 2022, down from $225.9M at year-end 2021; expected to fund operations through 2025.
Acumen reports FY2021 net loss $100.6M; Phase 1 ACU193 topline results expected H1 2023
Cash, cash equivalents and marketable securities $225.9M at Dec 31, 2021; provides runway through 2025.
James Doherty has been appointed as its President and Chief Development Officer, effective February 1, 2024.
Effective upon the commencement of Mr. Doherty's employment, Daniel O'Connell's position would be updated to Chief Executive Officer.
On January 3, 2023, the Board of Directors (the “ Board ”) of Acumen Pharmaceuticals, Inc. (the “ Company ”) approved the appointment of Dr. Derrell Porter to serve as a director on the Board, effective January 4, 2023 (the “ Effective Date ”).
On August 12, 2022, Dr. Jeffrey Sevigny notified the Board of Directors of his resignation from the Board of Directors, effective immediately.
Max materiality 0.90 · Median 0.60 · Most common event other_material